Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506058 | 0.92 | SCN8A (0.31) | — | |
| SCHEMBL6497945 | 0.90 | NTRK1 (0.30) | — | |
| SCHEMBL6508814 | 0.88 | ATF1 (0.30) | — | |
| SCHEMBL6499218 | 0.87 | LMNA (0.35) | CES2 | |
| SCHEMBL6501057 | 0.82 | MAPT (0.34) | — | |
| SCHEMBL6499655 | 0.81 | ALDH1A1 (0.30) | — | |
| SCHEMBL6510626 | 0.81 | TDP1 (0.34) | — | |
| SCHEMBL6508683 | 0.81 | SSTR3 (0.31) | — | |
| SCHEMBL6506994 | 0.80 | KMT2A (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL6504699 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | TRINE PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
| EP-1389463-A1 | MEDICINE FOR INHIBITING DRUG ELIMINATION PUMP | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | CES2 183/4885 |
| US-20050009843-A1 | Medicine for inhibiting drug elimination pump | ABCB11, ATP6AP1, HRH2 | CES2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.